Abstract GS2-07: MANTA - A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer

Phase Ii ◽

Mtor Inhibitor ◽

Phase Ii Study ◽

Metastatic Breast ◽

Randomized Phase Ii ◽

Abstract OT1-03-12: MANTA: A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer

10.1158/1538-7445.sabcs15-ot1-03-12 ◽

2016 ◽

Author(s):

P Schmid ◽

M Ferreira ◽

S Dubey ◽

M Zaiss ◽

C Harper-Wynne ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Phase Ii ◽

Mtor Inhibitor ◽

Phase Ii Study ◽

Metastatic Breast ◽

Randomized Phase Ii ◽

Abstract PD1-10: Randomized phase II study comparing two different schedules of palbociclib plus second line endocrine therapy in women with estrogen receptor positive, HER2 negative advanced/metastatic breast cancer: CCTG MA38 (NCT02630693)

10.1158/1538-7445.sabcs18-pd1-10 ◽

2019 ◽

Author(s):

WR Parulekar ◽

AA Joy ◽

K Gelmon ◽

M Mates ◽

C Desbiens ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Endocrine Therapy ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Second Line ◽

Randomized Phase Ii ◽

A phase II study of afatinib, an irreversible ErbB family blocker, added to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic breast cancer progressing on letrozole

SpringerPlus ◽

10.1186/s40064-015-1601-7 ◽

2016 ◽

Vol 5 (1) ◽

Cited By ~ 6

Author(s):

Katharina Gunzer ◽

Florence Joly ◽

Jean-Marc Ferrero ◽

Joseph Gligorov ◽

Helene de Mont-Serrat ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Erbb Family ◽

Estrogen Receptor Positive ◽

Erbb Family Blocker ◽

Hormone Refractory

Abstract P5-20-06: RAD001 (Everolimus) in combination with Letrozole in the treatment of postmenopausal women with estrogen receptor positive Metastatic Breast cancer after failure of hormonal therapy – a phase II study

10.1158/0008-5472.sabcs12-p5-20-06 ◽

2012 ◽

Cited By ~ 2

Author(s):

T Safra ◽

B Kaufman ◽

Baruch N Ben ◽

L Kadouri-Sonenfeld ◽

B Nisenbaum ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Postmenopausal Women ◽

Phase Ii ◽

Hormonal Therapy ◽

Phase Ii Study ◽

Metastatic Breast ◽

BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population

Annals of Oncology ◽

10.1093/annonc/mdz086 ◽

2019 ◽

Vol 30 (5) ◽

pp. 774-780 ◽

Cited By ~ 23

Author(s):

N.C. Turner ◽

E. Alarcón ◽

A.C. Armstrong ◽

M. Philco ◽

Y.A. López Chuken ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Dose Finding ◽

Akt Inhibitor ◽

Faculty Opinions recommendation of Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.734565867.793581155 ◽

2020 ◽

Author(s):

David Potter

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Neoadjuvant Therapy ◽

Early Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Randomized Phase Ii ◽

Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study

Annals of Oncology ◽

10.1093/annonc/mdx505 ◽

2018 ◽

Vol 29 (1) ◽

pp. 154-161 ◽

Cited By ~ 70

Author(s):

H.S. Han ◽

V. Diéras ◽

M. Robson ◽

M. Palácová ◽

P.K. Marcom ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Randomized Phase Ii ◽

Locally Recurrent

Randomized phase II study of single-agent epirubicin +/— verapamil in patients with advanced metastatic breast cancer

Annals of Oncology ◽

10.1093/oxfordjournals.annonc.a058356 ◽

1993 ◽

Vol 4 (1) ◽

pp. 45-50 ◽

Cited By ~ 35

Author(s):

K. Mross ◽

C. Bohn ◽

L. Edler ◽

W. Jonat ◽

W. Queisser ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Single Agent ◽

Metastatic Breast ◽

Randomized Phase Ii

START: A randomized phase II study in patients with triple negative, androgen receptor positive locally recurrent (unresectable) or metastatic breast cancer treated with darolutamide or capecitabine (UCBG-306)

Annals of Oncology ◽

10.1093/annonc/mdy272.356 ◽

2018 ◽

Vol 29 ◽

pp. viii120 ◽

Author(s):

H. Bonnefoi ◽

C. Levy ◽

G. MacGrogan ◽

T. Grellety ◽

B. Asselain ◽

...

Keyword(s):

Breast Cancer ◽

Androgen Receptor ◽

Phase Ii ◽

Triple Negative ◽

Phase Ii Study ◽

Metastatic Breast ◽

Randomized Phase Ii ◽

Locally Recurrent

P5-19-02: Comparison of the Incidence of Peripheral Neuropathy with Eribulin Mesylate Versus Ixabepilone in Metastatic Breast Cancer Patients: A Randomized Phase II Study.

10.1158/0008-5472.sabcs11-p5-19-02 ◽

2011 ◽

Author(s):

L Vahdat ◽

P Gopalakrishna ◽

AA Garcia ◽

C Vogel ◽

C Pellegrino ◽

...

Keyword(s):

Breast Cancer ◽

Peripheral Neuropathy ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Breast Cancer Patients ◽

Eribulin Mesylate ◽

Randomized Phase Ii